MPS IIIA: Clinical Trials

4 trials for MPS IIIA, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 enrolling by invitation, 1 not yet recruiting, 1 recruiting, 1 terminated. 2 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 22Recruiting 1, Terminated 1
Phase 32Enrolling by invitation 1, Recruiting 1
Phase 11Terminated 1

Follow MPS IIIA: new trials by email Literature Review of MPS IIIA trials Research Report on MPS IIIA

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
MPS IIIA Disease Monitoring Program
No Intervention - MPS IIIA, Sanfilippo Syndrome
Not yet recruitingUltragenyx Pharmaceutical Inc552026-11-012026-10-02
Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA
No Investigational Product, Adjuvant Immunomodulatory (IM) Therapy - Mucopolysaccharidosis IIIA, MPS IIIA
Phase 3Enrolling by invitationUltragenyx Pharmaceutical Inc412020-09-282026-07-17
Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease
ABO-102 - MPS IIIA, Sanfilippo Syndrome
Phase 1 / Phase 2TerminatedUltragenyx Pharmaceutical Inc52019-09-182023-07-25
Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH
UX111, Prophylactic Immunomodulatory (IM) Therapy, Optimized Prophylactic IM Therapy - MPS IIIA, Sanfilippo Syndrome
Phase 2 / Phase 3RecruitingUltragenyx Pharmaceutical Inc362016-04-252026-09-22

Narrower conditions

Mucopolysaccharidosis III (4)

Broader conditions

Carbohydrate Metabolism, Inborn Errors (4)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4)  ·  Connective Tissue Diseases (4)  ·  Genetic Diseases, Inborn (4)  ·  Lysosomal Storage Diseases (4)  ·  Metabolic Diseases (4)  ·  Metabolism, Inborn Errors (4)  ·  Mucinoses (4)  ·  Mucopolysaccharidoses (4)  ·  Nutritional and Metabolic Diseases (4)  ·  Skin and Connective Tissue Diseases (4)

Interventions

Therapeutics (2)

Sponsors

Ultragenyx Pharmaceutical Inc (4)

Countries

Australia (3)  ·  Spain (3)  ·  United States (3)

Results publications

PMID 32884151

NIH funding

2023 (2), 2015 (1), 2018 (1), 2019 (1)